🔎 Trials Near Me

Home › Kanser sa Bato (Renal Cell Carcinoma) › Oregon

Pag-aaral pangklinika para sa Kanser sa Bato (Renal Cell Carcinoma) sa Oregon

11 pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) ang naghahanap ng mga kalahok sa mga site sa Oregon.

Mga Lungsod sa Oregon

Opisyal na teksto ng pag-aaral (English)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • at 7 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #51, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05176483

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • at 1 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT03866382

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • Northwest Cancer Specialists, P.C., Portland
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07227415

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  • Providence Newberg Medical Center, Newberg
  • Providence Willamette Falls Medical Center, Oregon City
  • Providence Portland Medical Center, Portland
  • at 2 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06661720

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  • Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT04895709

A Study of MGC026 in Participants With Advanced Solid Tumors

  • Providence Cancer Institute, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT06242470

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  • Oregon Health & Science University (3485 S. Bond), Portland
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 9, 2026 · NCT03972657

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

  • OHSU Knight Cancer Institute, Portland
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 12, 2026 · NCT07405086

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

  • Oregon Health & Science University, Portland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2025 · NCT06805825

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

  • Kaiser Sunnyside Medical Center, Clackamas
  • Kaiser Permanente Northwest, Portland
  • Oregon Health and Science University, Portland
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2025 · NCT04510597

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.